Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04369729
Other study ID # 20-003732
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 9, 2020
Est. completion date August 2024

Study information

Verified date January 2024
Source Mayo Clinic
Contact Dani Smith
Phone 480-342-6524
Email Smith.Dani@mayo.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a United States Department of Defense funded Focused Program study that aims to identify mechanisms and predictors for persistent of post-traumatic headache attributed to mild traumatic brain injury, and identify methods of preventing post-traumatic headache persistence


Description:

The human studies component of this Focused Program include clinical phenotyping, neurophysiology, molecular and genetic biomarker discovery, and brain imaging. This data will be utilized to characterize post-traumatic headache and build univariate and multivariate predictive models for post-traumatic headache persistence and for the response to post-traumatic headache treatment. Some participants might be eligible to participate in the clinical trial portion of this study.The clinical trial is a double-blind, randomized, placebo-controlled investigation of erenumab for the treatment of post-traumatic headache. Participants will be randomized when PTH has been present for 35-56 days. The clinical trial component of this Focused Program is described in more detail in a separate clinicaltrials.gov record. Follow-up questionnaires, headache diary data, pain threshold results, and brain imaging data will be collected longitudinally during the trial to assess for changes over time and associations of such changes with post-traumatic headache treatment outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 264
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility POST-TRAUMATIC HEADACHE ELIGIBILITY CRITERIA Inclusion Criteria: - Have a diagnosis of acute PTH attributed to mild traumatic injury to the head as defined by the International Classification of Headache Disorders (ICHD-3). - PTH onset 7-56 days prior to the time of enrollment. - Adults 18-70 years of age. - Willing to maintain a headache diary. - Willing and able to return for follow-up visits. Exclusion Criteria: - Chronic headache (i.e. at least 15 headache days/month for more than 3 months) within 12 months prior to the mTBI that led to the current PTH, including PPTH, chronic migraine, medication overuse headache, new daily persistent headache, hemicrania continua, chronic tension-type headache. - Diminished decision-making capacity that in the investigator's opinion would interfere with the person's ability to provide informed consent and complete study procedures. - Started or changed dose of a headache preventive medication within the 3 months prior to screening. - Use of onabotulinumtoxinA in the head, neck or face region within 6 months of screening. - During the 6 months before screening, use of opioids or barbiturates on at least 4 days per month. - Subjects who underwent an intervention or used a device (e.g., nerve blocks, transcranial magnetic stimulation, vagal nerve stimulation, or electrical trigeminal nerve stimulation) for headache. - History of major psychiatric disorder such as schizophrenia and bipolar disorder. - History or evidence of any unstable or clinically significant medical condition, that in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion. - History of positive neuroimaging findings that indicate a moderate or severe TBI. - Contraindications to magnetic resonance imaging, including, but not limited to (only for those individuals participating in the MRI portion of this research): 1. Metal implants 2. Aneurysm clips 3. Severe claustrophobia 4. Implanted electronic devices 5. Insulin or infusion pump 6. Cochlear/otologic/ear implant 7. Non-removable prosthesis 8. Implanted shunts/catheters 9. Certain intrauterine devices 10. Tattooed makeup 11. Body piercings that cannot be removed 12. Metal fragments 13. Wire sutures or metal staples - Factors that reduce MR image quality and interpretability (only for those individuals participating in the MRI portion of this research): 1. Dental braces or other non-removable devices (e.g., retainers) 2. Prior brain surgery 3. Known brain MRI abnormality that in the investigator's opinion will significantly impact MRI data. - Sensory disorders that in the investigator's opinion might affect perception of cutaneous thermal stimuli (e.g., peripheral neuropathy) (only for those individuals undergoing pain threshold testing). - Pregnancy - Breastfeeding - Currently or within 90 days prior to screening: received treatment in another drug study or an investigational device study. HEALTHY CONTROL ELIGIBILITY CRITERIA Inclusion Criteria: - Adults 18-70 years of age. - Willing and able to return for follow-up visits. Exclusion Criteria: - History of traumatic brain injury. - History of migraine or other headaches (Tension-type headache up to an average of 3 days per month is allowed). - Diminished decision-making capacity that in the investigator's opinion would interfere with the person's ability to provide informed consent and complete study procedures. - During the 6 months before screening, use of opioids or barbiturates on an average of at least 4 days per month. - History of major psychiatric disorder such as schizophrenia and bipolar disorder. - History or evidence of any unstable or clinically significant medical condition, that in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion. - Contraindications to magnetic resonance imaging, including, but not limited to: 1. Metal implants 2. Aneurysm clips 3. Severe claustrophobia 4. Implanted electronic devices 5. Insulin or infusion pump 6. Cochlear/otologic/ear implant 7. Non-removable prosthesis 8. Implanted shunts/catheters 9. Certain intrauterine devices 10. Tattooed makeup 11. Body piercings that cannot be removed 12. Metal fragments 13. Wire sutures or metal staples - Factors that reduce MR image quality and interpretability: 1. Dental braces or other non-removable devices (e.g., retainers) 2. Prior brain surgery 3. Known brain MRI abnormality that in the investigator's opinion will significantly impact MRI data. - Sensory disorders that in the investigator's opinion might affect perception of cutaneous thermal stimuli (e.g., peripheral neuropathy). - Pregnancy - Breastfeeding - Currently or within 90 days prior to screening: received treatment in another drug study or an investigational device study - Has previously received any CGRP ligand or receptor targeted monoclonal antibody

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Mayo Clinic Jacksonville Florida
United States Mayo Clinic Phoenix Arizona
United States Phoenix VA Health Care System Phoenix Arizona
United States Mayo Clinic Rochester Minnesota
United States Mayo Clinic Scottsdale Arizona

Sponsors (7)

Lead Sponsor Collaborator
Mayo Clinic Amgen, Arizona State University, Phoenix VA Health Care System, Translational Genomics Research Institute, United States Department of Defense, University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Longitudinal Assessment of PTH Phenotype descriptive analysis of post-traumatic headache characteristics such as headache frequency and severity, and characteristics of associated conditions such as symptoms of sensory hypersensitivities, anxiety, depression, insomnia, autonomic dysfunction, and cognitive function baseline with longitudinal follow-up at weeks four and sixteen
Primary Longitudinal Assessment of Cutaneous Pain Thresholds heat pain thresholds on the skin determined by quantitative sensory testing baseline with longitudinal follow-up at weeks four and sixteen
Primary Longitudinal Assessment of Visual Pain Thresholds from Bright Light Exposure visual pain thresholds to different light intensities baseline with longitudinal follow-up at weeks four and sixteen
Primary Longitudinal Assessment of Brain MRI structural brain imaging to include measures such as cortical thickness, regional volumes, brain curvature, white matter tract integrity, and functional brain imaging measures such as resting state functional connectivity and pain-induced brain activation baseline with longitudinal follow-up at weeks four and sixteen
Primary Longitudinal Assessment of Blood Based Biomarkers blood-based biomarkers, including DNA and targeted serum proteins, associated with acute and persistent post-traumatic headache and response to therapy baseline with longitudinal follow-up at weeks four and sixteen
Primary Longitudinal Assessment of Post-traumatic Headache Biomarkers clinical characteristics, pain thresholds, and brain imaging features as described above that are associated with acute post-traumatic headache and persistent post-traumatic headache; that predict the persistent of post-traumatic headache; and that predict and measure treatment response baseline with longitudinal follow-up at weeks four and sixteen
See also
  Status Clinical Trial Phase
Completed NCT03588364 - The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine N/A
Recruiting NCT05378074 - Hypersensitivity to Opening of BKCa Channels in Post-Traumatic Headache N/A
Recruiting NCT05328635 - Post-traumatic Headache Multidisciplinary Study
Completed NCT04776304 - Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms N/A
Recruiting NCT04614922 - Acceptance and Commitment Therapy-based Rehabilitation of Post-concussion Symptoms N/A
Recruiting NCT05595993 - Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache N/A
Completed NCT03674398 - Aerobic Exercise and Cognitive Training Effects on Postconcussive Symptomology N/A
Completed NCT02965027 - Prazosin for Post-Concussive Headaches Phase 4
Active, not recruiting NCT05635656 - Digital Solutions for Concussion N/A
Recruiting NCT06015451 - Exercise in Postconcussion Symptoms and Posttraumatic Headache N/A
Recruiting NCT04906603 - Theta Burst Stimulation for Headaches After Traumatic Brain Injury N/A
Terminated NCT01053507 - Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction Phase 4
Completed NCT02419131 - Cognitive-Behavior Therapy for Posttraumatic Headache N/A
Terminated NCT03806985 - Effects of Psilocybin in Concussion Headache Phase 1
Completed NCT05243953 - Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache N/A
Completed NCT03056352 - Metoclopramide for Post-Traumatic Headache. A Pilot Study Phase 1/Phase 2
Recruiting NCT06132529 - A Study to Evaluate Biomarker Signature to Predict the Persistence of Post-traumatic Headache
Completed NCT01854385 - Sumatriptan as Treatment for Post-traumatic Headache Phase 2
Completed NCT03523923 - TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI) N/A
Recruiting NCT05378061 - Hypersensitivity to PACAP-38 in Post-Traumatic Headache N/A

External Links